The risk of recurrent venous thromboembolism: The Austrian study on recurrent venous thromboembolism

Wiener Klinische Wochenschrift

Volumn 115, Issue 13-14, 2003, Pages 471-474

  Kyrle, Paul Alexander ^a,b   Eichinger, Sabine ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b Universatatsklinik fur Anaesthesie   (Austria)

Author keywords

Recurrence; Thrombotic risk factors; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; PROTHROMBIN; VITAMIN;

ANTICOAGULATION; GENE MUTATION; HUMAN; HYPERHOMOCYSTEINEMIA; LUNG EMBOLISM; PROPHYLAXIS; RECURRENT DISEASE; REVIEW; RISK FACTOR; THROMBOEMBOLISM; VEIN THROMBOSIS; VITAMIN SUPPLEMENTATION;

EID: 0041317700     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03041030     Document Type: Review

References (28)

1. Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, et al (1991) A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism: the Worcester DVT Study. Arch Intern Med 151: 933-938
2. Douketis JD, Kearon C, Bates S, Duku EK, Ginsberg JS (1998) Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA 279: 458-462
3. Levine MN, Raskob G, Landefeld S, Kearon C (1998) Hemorrhagic complications of anticoagulant treatment. Chest 114: 511S-523S
4. van den Belt AG, Sanson BJ, Simioni P, Prandoni P, Buller HR, Girolami A, et al (1997) Recurrence of venous thromboembolism in patients with familial thrombophilia. Arch Intern Med 157: 2227-2232
5. Schulman S, Granqvist S, Holmstrom M, Carlsson A, Lindmarker P, Nicol P, et al (1997) The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagualtion Trial Study Group. N Engl J Med 336: 393-398
6. Prandoni P, Lensing AW, Cogo A, Cuppini S, Villalta S, Carta M, et al (1996) The long-term clinical corse of acute deep venous thrombosis. Ann Intern Med 125: 1-7
7. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR (1995) The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 332: 993-997
8. De Stefano V, Martinelli I, Mannucci PM, Paciaroni K, Chiusolo P, Casorelli I, et al (1999) The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med 341: 801-806
9. Schulman S, Rhedin AS, Lindmarker P, Carlsson A, Larfars G, Nicol P, et al (1995) A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J Med 332: 1661-1665
10. Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR, et al (1999) A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 340: 901-907
11. Pinede L, Ninet J, Duhaut P, Chabaud S, Demolombe-Rague S, Durieu I, et al (2001) Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation 103: 2453-2460
12. Agnelli G, Prandoni P, Santamaria MG, Bagattella P, Iorio A, Bazzan M, et al (2001) Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. N Engl J Med 345: 165-169
13. Kalbfleisch JD, Prentice RL (1980) The statistical analysis of failure time data. Wiley, New York
14. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481
15. Kyrle PA, Eichinger S (2002). The risk of recurrent venous thromboembolism. VASA 31: 163-166
16. Kyrle PA, Mannhalter C, Beguin S, Stümpflen A, Hirschl M, Weltermann A, et al (1998) Clinical studies and thrombin generation in patients homozygous or heterozygous for the G20210A mutation in the prothrombin gene. Arterioscler Thromb Vasc Biol 18: 1287-1291
17. Kyrle PA, Stümpflen A, Hirschl M, Bialonczyk C, Herkner K, Speiser W, et al (1997) Heightened hemostatic system activation in patients with elevated plasma levels of homocystein and a histoty of venous thromboembolism. Thromb Haemost 78: 1327-1331
18. Kyrle PA, Eichinger S, Pabinger I, Stümpflen A, Hirschl M, Bialonczyk C, et al (1997) Prothrombin fragment F1+2 is not predictive for recurrent venous thromboembolism. Thromb Haemost 77: 829-833
19. Eichinger S, Pabinger I, Stümpflen A, Hirschl M, Bialonczyk C, Schneider B, et al (1997) The risk of recurrent venous thromboembolism in patients without and with Facor V Leiden. Thromb Haemost 77: 624-628
20. Eichinger S, Stümpflen A, Hirschl M, Bialonczyk C, Herkner K, Schneider B, et al (1998) Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism. Thromb Haemost 80: 566-569
21. Eichinger S, Minar E, Hirschl M, Bialonczyk C, Stain M, Mannhalter C, et al (1999) The risk of early recurrent venous thromboembolism after oral anticoagulant therapy in patients with the G20210A transition in the prothrombin gene. Thromb Haemost 81: 14-17
22. Kyrle PA, Minar E, Hirschl M, Bialonczyk C, Stain M, Schneider B, et al (2000) High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 343: 457-462
23. Eichinger S, Weltermann A, Mannhalter C, Minar E, Bialonczyk C, Hirschl M, et al (2002) The risk of recurrent venous thromboembolism in heterozygous carriers of factor V Leiden and a first spontaneous venous thromboembolism. Arch Intern Med 162: 2357-2360
24. Weltermann A, Eichinger S, Bialonczyk C, Minar E, Hirschl M, Quehenberger P, et al (2003) The risk of recurrent venous thromboembolism among patients with high factor IX levels. J Thromb Haemost (in press)
25. Eichinger S, Weltermann A, Minar E, Stain M, Schönauer V, Schneider B, et al (2003) Symptomatic pulmonary embolism and the risk of recurrent venous thromboembolism. Arch Intern Med (in press)
26. Schönauer V, Kyrle PA, Partsch H, Weltermann A, Minar E, Bialonczyk C, et al (2003) Superficial venous thrombophlebitis and the risk of recurrent venous thromboembolism. J Vasc Surg (in press)
27. Kraaijenhagen RA, Hoppener MR, Levi M, Büller HR (2001) Beta-receptor blockade decreases elevated plasma levels of factor VIIIc in patients with deep vein thrombosis. The etiology of this important riskfactor revealed? Blood 96: 450A
28. Schulman S (1999) The effect of the duration of anticoagulation and other risk factors on the recurrence of venous thromboembolism. Wien Med Wochenschr 149: 66-69